{"id":32055,"date":"2025-04-18T18:13:46","date_gmt":"2025-04-18T10:13:46","guid":{"rendered":"https:\/\/flcube.com\/?p=32055"},"modified":"2025-04-18T18:13:47","modified_gmt":"2025-04-18T10:13:47","slug":"velavigo-and-ollin-biosciences-ink-licensing-deal-for-first-in-class-bsab-vbs-102","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32055","title":{"rendered":"Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102"},"content":{"rendered":"\n

Velavigo, a biotech company with operations in Shanghai, China, and Boston, USA, has entered into a licensing agreement with Ollin Biosciences, Inc. This strategic partnership grants Ollin exclusive development, manufacturing, and commercialization rights to Velavigo\u2019s VBS-102, a first-in-class bispecific antibody (BsAb), on a global scale excluding Greater China. Velavigo will retain rights for Greater China.<\/p>\n\n\n\n

Financial Terms of the Agreement<\/strong>
Under the terms of the agreement, Velavigo will receive up to USD 440 million in total payments. This includes an upfront fee and future development, regulatory, and commercial milestone payments. Additionally, Velavigo will be entitled to tiered royalties based on sales performance.<\/p>\n\n\n\n

Product Profile and Future Outlook<\/strong>
VBS-102 is a first-in-class bispecific antibody developed by Velavigo. The licensing agreement underscores the potential of this innovative therapeutic candidate and positions Ollin Biosciences to leverage its global footprint to bring this novel therapy to patients outside Greater China.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Velavigo, a biotech company with operations in Shanghai, China, and Boston, USA, has entered into…<\/p>\n","protected":false},"author":1,"featured_media":32057,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[28,4016,25,2191],"class_list":["post-32055","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-multi-specific-antibodies","tag-ollin-biosciences","tag-potential-first-in-class","tag-velavigo"],"yoast_head":"\nVelavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Velavigo, a biotech company with operations in Shanghai, China, and Boston, USA, has entered into a licensing agreement with Ollin Biosciences, Inc. This strategic partnership grants Ollin exclusive development, manufacturing, and commercialization rights to Velavigo\u2019s VBS-102, a first-in-class bispecific antibody (BsAb), on a global scale excluding Greater China. Velavigo will retain rights for Greater China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32055\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102\" \/>\n<meta property=\"og:description\" content=\"Velavigo, a biotech company with operations in Shanghai, China, and Boston, USA, has entered into a licensing agreement with Ollin Biosciences, Inc. This strategic partnership grants Ollin exclusive development, manufacturing, and commercialization rights to Velavigo\u2019s VBS-102, a first-in-class bispecific antibody (BsAb), on a global scale excluding Greater China. Velavigo will retain rights for Greater China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32055\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-18T10:13:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-18T10:13:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1816.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32055#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32055\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102\",\"datePublished\":\"2025-04-18T10:13:46+00:00\",\"dateModified\":\"2025-04-18T10:13:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32055\"},\"wordCount\":161,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32055#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1816.webp\",\"keywords\":[\"Multi-specific antibodies\",\"Ollin Biosciences\",\"Potential first-in-class\",\"VelaVigo\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32055#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32055\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32055\",\"name\":\"Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32055#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32055#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1816.webp\",\"datePublished\":\"2025-04-18T10:13:46+00:00\",\"dateModified\":\"2025-04-18T10:13:47+00:00\",\"description\":\"Velavigo, a biotech company with operations in Shanghai, China, and Boston, USA, has entered into a licensing agreement with Ollin Biosciences, Inc. This strategic partnership grants Ollin exclusive development, manufacturing, and commercialization rights to Velavigo\u2019s VBS-102, a first-in-class bispecific antibody (BsAb), on a global scale excluding Greater China. Velavigo will retain rights for Greater China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32055#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32055\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32055#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1816.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1816.webp\",\"width\":1080,\"height\":608,\"caption\":\"Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32055#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102 - Insight, China's Pharmaceutical Industry","description":"Velavigo, a biotech company with operations in Shanghai, China, and Boston, USA, has entered into a licensing agreement with Ollin Biosciences, Inc. This strategic partnership grants Ollin exclusive development, manufacturing, and commercialization rights to Velavigo\u2019s VBS-102, a first-in-class bispecific antibody (BsAb), on a global scale excluding Greater China. Velavigo will retain rights for Greater China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32055","og_locale":"en_US","og_type":"article","og_title":"Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102","og_description":"Velavigo, a biotech company with operations in Shanghai, China, and Boston, USA, has entered into a licensing agreement with Ollin Biosciences, Inc. This strategic partnership grants Ollin exclusive development, manufacturing, and commercialization rights to Velavigo\u2019s VBS-102, a first-in-class bispecific antibody (BsAb), on a global scale excluding Greater China. Velavigo will retain rights for Greater China.","og_url":"https:\/\/flcube.com\/?p=32055","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-18T10:13:46+00:00","article_modified_time":"2025-04-18T10:13:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1816.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32055#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32055"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102","datePublished":"2025-04-18T10:13:46+00:00","dateModified":"2025-04-18T10:13:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32055"},"wordCount":161,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32055#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1816.webp","keywords":["Multi-specific antibodies","Ollin Biosciences","Potential first-in-class","VelaVigo"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32055#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32055","url":"https:\/\/flcube.com\/?p=32055","name":"Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32055#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32055#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1816.webp","datePublished":"2025-04-18T10:13:46+00:00","dateModified":"2025-04-18T10:13:47+00:00","description":"Velavigo, a biotech company with operations in Shanghai, China, and Boston, USA, has entered into a licensing agreement with Ollin Biosciences, Inc. This strategic partnership grants Ollin exclusive development, manufacturing, and commercialization rights to Velavigo\u2019s VBS-102, a first-in-class bispecific antibody (BsAb), on a global scale excluding Greater China. Velavigo will retain rights for Greater China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32055#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32055"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32055#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1816.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1816.webp","width":1080,"height":608,"caption":"Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32055#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1816.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32055"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32055\/revisions"}],"predecessor-version":[{"id":32058,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32055\/revisions\/32058"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32057"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32055"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32055"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}